Latest:
Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma
Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ajay K. Gopal, MD, FACP
Ajay K. Gopal, MD, FACP, is the medical director for Hematology, Malignancies/Hematology, the clinical research director for the Lymphoma Program and an professor in the Clinical Research Division at Fred Hutch Cancer Center; professor of Hematology and Oncology in the Division of Hematology and Oncology at the University of Washington School of Medicine, and the Stephen Hans Petersdorf, MD, Endowed Chair in Cancer Care at the University of Washington Medicine, both located in Washington.
Latest:
Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma
Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.
Ajay K. Nooka, MD, MPH, FACP
Latest:
EHA 2025 Insights: Emerging Developments and Future Perspectives for the Multiple Myeloma Treatment Landscape
Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.
Ajay S. Behl, PhD
Latest:
CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC
Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.
Ajay V. Maker, MD, FACS
Latest:
New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases
Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.
Akash Patnaik, MD, PhD
Latest:
Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC
Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Akihiko Shimomura, MD, PhD
Latest:
Dr. Shimomura Discusses the HERB TEA Study in HER2+ Breast Cancer
Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.